Please login to the form below

Not currently logged in
Email:
Password:

Takeda wins UK approval for cancer drug

Takeda's bone cancer treatment Mepact has won the backing of the UK's National Institute for Health and Clinical Excellence

Takeda Pharmaceutical won the backing of the UK's National Institute for Health and Clinical Excellence (NICE) for its Mepact (mifamurtide) drug, for the treatment of high-grade resectable non-metastic osteosarcoma.

Mepact is approved for use with chemotherapy after surgery for bone cancers that have not spread. The approval is conditional on Takeda providing a price discount, which it has agreed to do, according to NICE.

The agency reversed a decision from 2010 in which it rejected the drug. The initial economic analysis may not have adequately captured the health-related quality of life from the drug, NICE said.

The terms of the discount have not been disclosed at Takeda's request.

Takeda acquired the rights to Mepact when it purchased IDM Pharma in May, 2009.

7th September 2011

From: Healthcare

Share

Related Hub content

    Your search did not contain any words. Please try again.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Life

What is Life? Life is whatever you want it to be. Attention-grabbing advertising. Incisive strategic ideas. Dynamic brand development. Integrated...

Latest intelligence

Online Physician Communities
Research finds doctors are optimistic about new diabetes drugs but concerned over rationing
New data from M3 Global Research shows that clinicians buy in to the effectiveness of new diabetes therapies. However, they are concerned about rationing and believe that more resources are...
McCann.jpg
The heart of the matter: Part Two
How is social media impacting publication planning?...
digital numbers
Seven steps to innovating your digital strategy
Dealing with digitally native HCPs...